ReviewEuropean psychiatry : the journal of the Association of European Psychiatrists2022
European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia.
Review in European psychiatry : the journal of the Association of European Psychiatrists, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 6 syntheses or guidelines pooled it, 122 citations in OpenAlex.
- Effectiveness of different exercise therapies in patients with schizophrenia: A systematic review and network meta-analysis.Medicine · 2026Pooled it
- Efficacy and safety of tACS in older adults with cognitive impairment: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- Suicidal risk in patients with aggression in schizophrenia: a systematic review.Frontiers in psychiatry · 2025Pooled it
- Cognitive rehabilitation in schizophrenia research: a bibliometric and visualization analysis.Frontiers in psychiatry · 2024Pooled it
- Metformin for neurocognitive dysfunction in schizophrenia: a systematic review.Frontiers in psychiatry · 2024Pooled it
- Topical Cellular/Tissue and Molecular Aspects Regarding Nonpharmacological Interventions in Alzheimer's Disease-A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Neurophysiological and autonomic effects of Cognitive Remediation Therapy in schizophrenia: a randomized controlled EEG-GSR study.BMC psychiatry · 2026Trial
- Group-activity cognitive remediation therapy on cognitive impairment in patients with chronic schizophrenia: a randomized controlled follow-up study.European archives of psychiatry and clinical neuroscience · 2026Trial
- Effectiveness of cognitive remediation in subjects with major depressive disorder: A multicenter randomized controlled study in a real-world setting.European psychiatry : the journal of the Association of European Psychiatrists · 2025Trial
- Executive dysfunction and cognitive disorganization in schizophrenia: Case-control and cluster analyses of a Korean Wisconsin Card Sorting Test cohort.Schizophrenia research. Cognition · 2026Article
- Clinical Utility of Cariprazine in the Management of Acute Schizophrenia: Current Evidence and Practical Recommendations.Actas espanolas de psiquiatria · 2026Review
- Exploring the impact of cognitive profiles on the response to magnetic seizure therapy and electroconvulsive therapy.Molecular psychiatry · 2026Article
- The Role of Long-Acting Injectable Antipsychotics in the Early Treatment of Schizophrenia.CNS drugs · 2026Review
- Clinical Factors Influencing Improvement in Disorganization in Clinical High-Risk for Psychosis: Preliminary Findings From a 2-Year Follow-Up.Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists · 2026Article
- Integrated clinical and postmortem profiling in schizophrenia reveals a cognitive subtype linked to cerebrovascular disease.Translational psychiatry · 2026Article
- How Can We Better Assist Caregivers With Understanding and Addressing the Cognitive Health Needs of People With Psychotic Disorders?Schizophrenia bulletin · 2026Review
- Virtual reality-based cognitive remediation in severe mental illness: Current evidence from a narrative review.Schizophrenia research. Cognition · 2026Review
- Implementing A Cognitive Screening Tool as Part of Routine Clinical Practice in Early Intervention for Psychosis Services: A Qualitative Analysis.Early intervention in psychiatry · 2026Article
- Overcoming Patient Access Barriers in Complex Conditions: Lessons from Schizophrenia for Broader Healthcare Applications.Journal of market access & health policy · 2026Article
- Moderating Role of Cigarette Smoking on the Efficacy of tDCS in the Treatment of Negative and Cognitive Symptoms of Schizophrenia: Results from a Randomized Clinical Trial.Brain sciences · 2026Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough cognitive impairment is a core symptom of schizophrenia related to poorer outcomes in different functional domains, it still remains a major therapeutic challenge. To date, no comprehensive treatment guidelines for cognitive impairment in schizophrenia are implemented.
methodsThe aim of the present guidance paper is to provide a comprehensive meta-review of the current available evidence-based treatments for cognitive impairment in schizophrenia. The guidance is structured into three sections: pharmacological treatment, psychosocial interventions, and somatic treatments.
resultsBased on the reviewed evidence, this European Psychiatric Association guidance recommends an appropriate pharmacological management as a fundamental starting point in the treatment of cognitive impairment in schizophrenia. In particular, second-generation antipsychotics are recommended for their favorable cognitive profile compared to first-generation antipsychotics, although no clear superiority of a single second-generation antipsychotic has currently been found. Anticholinergic and benzodiazepine burdens should be kept to a minimum, considering the negative impact on cognitive functioning. Among psychosocial interventions, cognitive remediation and physical exercise are recommended for the treatment of cognitive impairment in schizophrenia. Noninvasive brain stimulation techniques could be taken into account as add-on therapy.
conclusionsOverall, there is definitive progress in the field, but further research is needed to develop specific treatments for cognitive impairment in schizophrenia. The dissemination of this guidance paper may promote the development of shared guidelines concerning the treatment of cognitive functions in schizophrenia, with the purpose to improve the quality of care and to achieve recovery in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.